For an adult patient with obsessive‑compulsive disorder and no contraindications, how do fluvoxamine (Luvox) and paroxetine (Paxil) compare regarding efficacy, side‑effect profile, dosing schedule, and drug‑interaction considerations?

Luvox vs Paxil for OCD

Both fluvoxamine (Luvox) and paroxetine (Paxil) are equally effective first-line SSRIs for OCD, but paroxetine is generally preferred due to its superior tolerability profile and lower incidence of adverse events. 1

Efficacy: Essentially Equivalent

The 2019 Nature Reviews Disease Primers guideline explicitly states that "the effect sizes of SSRIs were similar in systematic reviews" for OCD treatment 1. A 1997 head-to-head single-blind study directly comparing fluvoxamine and paroxetine found no significant differences in antiobsessional efficacy between the two agents 2. Both drugs are FDA-approved for OCD and demonstrate similar response rates (38-52% for fluvoxamine vs placebo rates of 0-18%) 3.

Tolerability: Paroxetine Has the Advantage

The critical differentiator is tolerability. A large observational cohort study comparing all four major SSRIs found that fluvoxamine had a considerably higher incidence of side-effects and was associated with a higher incidence of adverse events than fluoxetine, sertraline, and paroxetine 4. Only 36% of physicians rated fluvoxamine as effective compared to approximately 60% for paroxetine, and fluvoxamine showed higher dropout rates 4.

Common Side Effects for Both:

• Nausea/vomiting (most frequent reason for discontinuation)
• Gastrointestinal symptoms
• Sexual dysfunction (abnormal ejaculation, decreased libido, anorgasmia)
• Insomnia or somnolence
• Sweating

Paroxetine-Specific Concern:

Withdrawal symptoms are significantly more frequent with paroxetine than other SSRIs, requiring careful tapering 4.

Dosing Schedule

Fluvoxamine (Luvox): 5

• Start: 50 mg at bedtime
• Titrate: Increase by 50 mg every 4-7 days
• Target range: 100-300 mg/day
• Doses >100 mg should be split twice daily (larger dose at bedtime)

Paroxetine (Paxil):

• Start: 20 mg daily
• Titrate: Increase by 10 mg weekly
• Target range: 40-60 mg/day (higher doses used in OCD per meta-analysis) 6
• Once-daily dosing

Drug Interaction Considerations

Fluvoxamine has more complex drug interactions 3:

• Potent inhibitor of CYP1A2 (major concern)
• Moderate inhibitor of CYP2C19 and CYP3A4
• Weak inhibitor of CYP2D6

Paroxetine:

• Strong inhibitor of CYP2D6 (primary concern)
• Minimal effect on other CYP enzymes

Clinical implication: Fluvoxamine requires more vigilance with drug interactions, particularly with medications metabolized by CYP1A2 (theophylline, clozapine, caffeine) and CYP3A4 substrates. Paroxetine's main interaction concern is with CYP2D6 substrates.

Treatment Duration

Both require 1:

• 8-12 weeks to assess efficacy (though improvement may be seen within 2-4 weeks)
• Minimum 12-24 months maintenance after achieving remission
• Many patients require longer-term treatment

Clinical Algorithm

1. First choice: Paroxetine 20-60 mg/day due to better tolerability profile and lower adverse event incidence
2. Consider fluvoxamine if:
   • Patient has significant CYP2D6-metabolized medication burden
   • Previous good response to fluvoxamine
   • Cost/availability issues favor fluvoxamine
3. Monitor closely for:
   • Sexual dysfunction (both agents)
   • Withdrawal symptoms (especially with paroxetine)
   • Drug interactions (especially with fluvoxamine)
4. If inadequate response after 8-12 weeks: Switch to alternative SSRI or consider augmentation strategies 1

Important Caveats

• Both carry black box warnings for treatment-emergent suicidality in adolescents and young adults 6
• Higher SSRI doses are needed for OCD than depression (paroxetine 60 mg, fluvoxamine 200-300 mg) 6
• Approximately 40-60% of patients fail to respond adequately to first-line SSRI monotherapy 1, 7
• Sexual dysfunction is common but underreported—routinely inquire about this side effect 5